(Q34249313)

31 July 2017

0 references

Corticosteroid therapy in IgA nephropathy (English)

1 reference

31 July 2017

Vlado Perkovic

3

0 references

David Johnson

object named as

David W Johnson

5

0 references

Adeera Levin

7

object named as

Adeera Levin

1 reference

31 July 2017

Jicheng Lv

1

1 reference

31 July 2017

Damin Xu

2

1 reference

31 July 2017

Xinxin Ma

4

1 reference

31 July 2017

Mark Woodward

6

1 reference

31 July 2017

Hong Zhang

8

1 reference

31 July 2017

Haiyan Wang

9

1 reference

31 July 2017

TESTING Study Group

10

1 reference

31 July 2017

publication date

26 April 2012

1 reference

Journal of the American Society of Nephrology

31 July 2017

published in

1 reference

31 July 2017

volume

23

1 reference

31 July 2017

issue

6

1 reference

31 July 2017

page(s)

1108-1116

1 reference

Steroids in the treatment of IgA nephropathy to the improvement of renal survival: a systematic review and meta-analysis

31 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3358763

Non-immunosuppressive treatment for IgA nephropathy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3358763

Predicting the risk for dialysis or death in IgA nephropathy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3358763

Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3358763

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3358763

Efficacy and safety of glucocorticoids therapy for IgA nephropathy: a meta-analysis of randomized controlled trials

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3358763

Analyzing antibody activity in IgA nephropathy.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3358763

Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3358763

Immunosuppressive agents for treating IgA nephropathy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3358763

Measuring inconsistency in meta-analyses

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3358763

Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3358763

Corticosteroids in IgA nephropathy: a randomised controlled trial

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3358763

The commonest glomerulonephritis in the world: IgA nephropathy.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3358763

Can meta-analyses be trusted?

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3358763

Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3358763

Clinical assessment of low-dose steroid therapy for patients with IgA nephropathy: a prospective study in a single center

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3358763

Natural history of immunoglobulin A nephropathy and predictive factors of prognosis: a long-term follow up of 204 cases in China

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3358763

Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3358763

Controlled, prospective trial of steroid treatment in IgA nephropathy: a limitation of low-dose prednisolone therapy

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3358763

Bias in meta-analysis detected by a simple, graphical test. Experts' views are still needed

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3358763

28 October 2018

1 reference

12 December 2020

Corticosteroid therapy in IgA nephropathy with nephrotic syndrome: a long-term controlled trial

1 reference

12 December 2020

IgA nephropathy, the most common glomerulonephritis worldwide. A neglected disease in the United States?

1 reference

12 December 2020

Alternate-day prednisone therapy in IgA nephropathy. Preliminary analysis of a prospective, randomized, controlled trial

1 reference

12 December 2020

Clinical trial to evaluate omega-3 fatty acids and alternate day prednisone in patients with IgA nephropathy: report from the Southwest Pediatric Nephrology Study Group

1 reference

12 December 2020

Remission of proteinuria improves prognosis in IgA nephropathy

1 reference

12 December 2020

Supportive Versus Immunosuppressive Therapy of Progressive IgA nephropathy (STOP) IgAN trial: rationale and study protocol

1 reference

12 December 2020

Early treatment with corticosteroids ameliorates proteinuria, proliferative lesions, and mesangial phenotypic modulation in adult diffuse proliferative IgA nephropathy

1 reference

12 December 2020

Identifiers

DOI

10.1681/ASN.2011111112

1 reference

31 July 2017

1 reference

31 July 2017

1 reference